Vigabatrin and visual field defects in pediatric epilepsy patients

Journal of Korean Medical Science

Volumn 21, Issue 4, 2006, Pages 728-732

  Su, Jeong You ^a   Ahn, HyoSook ^a   Ko, Tae Sung ^a,b  

^a University of Ulsan College of Medicine   (South Korea)

^b University of Ulsan   (South Korea)

Author keywords

Epilepsy; Pediatric; Vigabatrin; Visual Fields

Indexed keywords

EID: 33746917944     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2006.21.4.728     Document Type: Review

References (29)

1. Ben-Menachem E. Vigabatrin. Epilepsia 1995; 36 (Suppl 2): 95-104.
2. Hancock E, Osborne JP. Vigabatrin in the treatment of infantile spasms in tuberous sclerosis: literature review. J Child Neurol 1999; 14: 71-4.
3. Eke T, Talbot JF, Lawden MC. Severe persistent visual field constriction associated with vigabatrin. BMJ 1997; 314: 180-1.
4. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Concentric contraction of the visual field in patients with temporal lobe epilepsy and its association with the use of vigabatrin medication. Epilepsia 2000; 41: 581-7.
5. Hardus P, Verduin WM, Postma G, Stilma JS, Berendschot TT, van Veelen CW. Long term changes in the visual fields of patients with temporal lobe epilepsy using vigabatrin. Br J Ophthalmol 2000; 84: 788-90.
6. Manuchehri K, Goodman S, Siviter L, Nightingale S. A controlled study of vigabatrin and visual abnormalities. Br J Ophthalmol 2000; 84: 499-505.
7. Vanhatalo S, Nousiainen I, Eriksson K, Rantala H, Vainionpää L, Mustonen K, Äärimaa T, Alen R, Aine MR, Byring R, Hirvasniemi A, Nuutila A, Walden T, Ritanen-Mohammed UM, Karttunen-Lewandowski P, Pohjola LM, Kaksonen S, Jurvelin P, Granströmet LM. Visual field constriction in 91 Finnish children treated with vigabatrin. Epilepsia 2000; 43: 748-56.
8. Malmgren K, Ben-Menachen E, Frisén L. Vigabatrin visual toxicity: Evolution and dose dependence. Epilepsia 2001; 42: 609-15.
9. Kälviäinen R, Nousiainen I, Mäntyjärvi M, Nikoskelainen E, Partanen J, Partanen K, Riekkinen P. Vigabatrin, a GABAergic antiepileptic drug, causes concentric visual field defects. Neurology 1999; 53: 922-6.
10. Wild JM, Martinez C, Reinshagen G, Harding GF. Characteristics of a unique visual field defect attributed to vigabatrin. Epilepsia 1999; 40: 1784-94.
11. Krauss GL, Johnson MA, Miller NR. Vigabatrin-associated retinal cone system dysfunction: electroretinogram and ophthalmologic findings. Neurology 1998; 50: 614-8.
12. Arndt CF, Derambure P, Defoort-Dhellemmes S, Hache JC. Outer retinal dysfunction in patients treated with vigabatrin. Neurology 1999; 52: 1201-5.
13. Iannetti P, Spalice A, Perla FM, Conicella E, Raucci U, Bizzarri B. Visual field constriction in children with epilepsy on vigabatrin treatment. Pediatrics 2000; 106: 838-42.
14. Vanhatalo S, Pääkkönen L, Nousiainen I. Visual field constriction in children treated with vigabatrin. Neurology 1999; 52: 1713-4.
15. Gross-Tsur V, Banin E, Shahar E, Shalev RS, Lahat E. Visual impairment in children with epilepsy treated with vigabatrin. Ann Neurol 2000; 48: 60-4.
16. Wohlrab G, Boltshauser E, Schmitt B, Schriever S, Landau K. Visual field constriction is not limited to children treated with vigabatrin. Neuropediatrics 1999; 30: 130-2.
17. Miller NR, Johnson MA, Paul SR, Girkin CA, Perry JD, Endres M, Krauss GL. Visual dysfunction receiving vigabatrin: Clinical and electrophysiologic findings. Neurology 1999; 53: 2082-7.
18. Toggweiler S, Wieser HG. Concenteric visual filed restriction under vigabatrin therapy: extent depends on the duration of drug intake. Seizure 2001; 10: 420-3.
19. Appleton RE, Peters AC, Mumford JP, Shaw DE. Randomized, placebo-controlled study of vigabatrin as first-line treatment of infantile spasms. Epilepsia 1999; 40: 1627-33.
20. Schmit T, Ruther K, Jokiel B, Pfeiffer S, Tiel-Wilck K, Schmitz B. Is visual field constriction in epilepsy patients treated with vigabatrin reversible? J Neurol 2002; 249 : 1066-71.
21. Johnson MA, Krauss GL, Miller NR, Medura M, Paul SR. Visual function loss from vigabatrin: effect of stopping the drug. Neurology 2000; 55: 40-5.
22. Krakow K, Polizzi G, Riordan-Eva, P, Holder G, MacLeod WN, Fish DR. Recovery of visual constriction following discontinuation of vigabatrin. Seizure 2000; 9: 287-90.
23. Fledelius HC. Vigabatrin associated visual field constriction in a longitudinal series. Reversibility suggested after drug withdrawal. Acta Ophthalmol Scand 2003; 81: 41-6.
24. Versino M, Veggiotti P. Reversibility of vigabatrin-induced visual-field defect. Lancet 1999; 354: 486.
25. Giordano L, Valseriati D, Vignoli A, Morescalchi F, Gandolfo E. Another case of reversibility of visual-defect induced by vigabatrin monotherapy: is young age a favorable factor? Neurol Sci 2000; 21: 185-6.
26. Nousiainen I, Kalviainen R, Mantyjarvi M. Contrast and glare sensitivity in epilepsy patients treated with vigabatrin or carbamazepine monotherapy compared with healthy volunteers. Br J Ophthalmol 2000; 84: 622-5.
27. Lawden MC, Eke T, Degg C, Harding GF, Wild JM. Visual field defects associated with vigabatrin therapy. J Neurol Neurosurg Psychiatry 1999; 67: 716-22.
28. Daneshvar H, Racette L, Coupland SG, Kertes PJ, Guberman A, Zackon D. Symptomatic and asymptomatic visual loss in patients taking vigabatrin. Ophthalmology 1999; 106: 1792-8.
29. Hardus P, Verduin WM, Engelsman M, Edelbroek PM, Segers JP, Berendschot TT, Stilma JS. Visual field loss associated with vigabatrin: quantification and relation to dosage. Epilepsia 2001; 42: 262-7.